Business
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new tethered continuous oxygen monitoring products for high impact clinical applications BERKELEY, Calif, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform seeking to en
About this update from Profusa, Inc.
[{"type":"image","alt":"Profusa, Inc.","displaySize":"","headline":null,"caption":"Profusa, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/8f79cba194228307ca23a2955a9ec150"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C0XqXJTHmuw3t23BmCcCpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEyODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8f79cba194228307ca23a2955a9ec150","width":200,"height":71}},"lazy":false},{"type":"text","content":"Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product ","length":154,"tagName":"p"},{"type":"text","content":"Seeking to develop and commercialize new tethered continuous oxygen monitoring products for high impact clinical applications","length":125,"tagName":"p"},{"type":"text","content":"BERKELEY, Calif, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform seeking to enable the continuous monitoring of an individual’s biochemistry, has entered into a know-how agreement with Mayo Clinic. The collaboration entails investigation of high impact clinical applications of Profusa’s oxygen monitoring technologies for new product development and commercialization. Potential target indications include cardiovascular, renal, multi-organ, and orthopedic applications, among others, where intra-organ postoperative perfusion monitoring has potential to improve clinical outcomes. The collaboration also supports Profusa’s potential commercialization of Lumee oxygen sensing and tissue monitoring technology for chronic limb threatening ischemia (CLTI) in the U.S.","length":919,"tagName":"p"},{"type":"text","content":"Michael Kendrick, M.D., Chair of Department of Surgery at Mayo Clinic, Rochester, Minn., said, “Oxygen is essential for cellular metabolism and tissue repair, with lack of sufficient oxygenation impairing wound healing, increasing risk of infection, and contributing to complications common to surgery, such as leakage and anastomotic structure. Our collaboration gives us the opportunity to leverage their innovative platform to potentially address unmet clinical challenges, including ...